Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Eton Pharmaceuticals licensed the U.S. rights to ASN-001, a late-stage topical treatment for infantile hemangiomas, from Auson Pharmaceuticals to complement its existing HEMANGEOL franchise. Phase II/III trial results showed that 56% of patients treated twice daily achieved elimination or near-elimination of hemangiomas at week 24, compared to 15% for placebo.
Key figures
- Drug Name
- ASN-001 (timolol topical gel)
- Phase Of Trial
- Phase II/III
- Patent expiry
- 2044
- Trial patients
- 168
- Response rate bid
- 56%
- Response rate tid
- 42%
- Response rate placebo
- 15%
- Target annual patients
- 20,000 to 30,000
- Nda submission timeline
- 2H 2027
- Off label patients annually
- >10,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.